Referred to the Subcommittee on Health.
The bill directs the Secretary of Veterans Affairs to either reimburse State veteran homes for certain "costly medications" or to furnish those medications directly, at the election of the covered State home. A "costly medication" is defined by a formula: if the average wholesale price for a one‑month supply plus a 3% transaction fee exceeds 8.5% of the monthly payment the VA makes to that State home for the veteran’s care.
Disagreement over federal cost expansion versus veterans' access
Relative to its intended legislative type, this bill is a narrowly focused substantive change that adds a statutory reimbursement/furnishing option for certain high-cost medications for veterans in State homes and supplies a specific definition of 'costly medication.' It integrates into the cited provision of existing law but omits several operational, fiscal, and oversight details.
The bill directs the Secretary of Veterans Affairs to either reimburse State veteran homes for certain "costly medications" or to furnish those medications directly, at the election of the covered State home.
A "costly medication" is defined by a formula: if the average wholesale price for a one‑month supply plus a 3% transaction fee exceeds 8.5% of the monthly payment the VA makes to that State home for the veteran’s care.
The provision applies to State homes providing nursing home care under VA contract or agreement.
Small, technical veterans' aid with low ideological resistance but uncertain fiscal impact and need for funding make passage plausible but not guaranteed.
Relative to its intended legislative type, this bill is a narrowly focused substantive change that adds a statutory reimbursement/furnishing option for certain high-cost medications for veterans in State homes and supplies a specific definition of 'costly medication.' It integrates into the cited provision of existing law but omits several operational, fiscal, and oversight details.
Disagreement over federal cost expansion versus veterans' access
These are examples from the analysis, not a ranked list of the most-affected groups.
Disagreement over federal cost expansion versus veterans' access
Likely supportive because it expands veterans' access to expensive medicines and reduces financial strain on State veteran homes.
May push for broader coverage, stronger price controls, and transparency around costs and implementation.
Concerned about any gaps that leave veterans without needed drugs.
Generally favorable because it's a targeted, narrow support for veterans in State homes, but wants clear budgetary estimates and implementation rules.
Seeks safeguards against cost growth and administrative complexity.
Would favor measured, time-limited rollout or evaluation.
Mixed to somewhat skeptical: supportive of better veterans' care but wary of expanding VA obligations and federal spending.
Concerned about increased bureaucracy, procurement responsibilities, and long-term budgetary effects.
May seek offsets or narrower scope.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Small, technical veterans' aid with low ideological resistance but uncertain fiscal impact and need for funding make passage plausible but not guaranteed.
The bill has not accumulated any surfaced votes yet.
Disagreement over federal cost expansion versus veterans' access
Small, technical veterans' aid with low ideological resistance but uncertain fiscal impact and need for funding make passage plausible but…
Relative to its intended legislative type, this bill is a narrowly focused substantive change that adds a statutory reimbursement/furnishing option for certain high-cost medications for veterans in State homes and suppl…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.